D.E. Shaw & Co
NKTR icon

D.E. Shaw & Co’s Nektar Therapeutics NKTR Stock Holding History

D.E. Shaw & Co’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-3,000
Closed -$971K – 4140
2019
Q4 		$971K Hold
3,000
– – ﹤0.01% 3008
2019
Q3 		$820K Hold
3,000
– – ﹤0.01% 2928
2019
Q2 		$1.6M Hold
3,000
– – ﹤0.01% 2390
2019
Q1 		$1.51M Sell
3,000
-1,000
-25% -$593K ﹤0.01% 2344
2018
Q4 		$1.97M Buy
4,000
+1,000
+33% +$604K ﹤0.01% 2161
2018
Q3 		$2.74M Hold
3,000
– – ﹤0.01% 1976
2018
Q2 		$2.2M Buy
3,000
+667
+29% +$769K ﹤0.01% 2158
2018
Q1 		$3.72M Buy
2,333
+1,666
+250% +$2.15M 0.01% 1604
2017
Q4 		$597K Buy
+667
New +$395K ﹤0.01% 2878

Other funds holding NKTR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co's NKTR Position: Q2 2025 in Review

D.E. Shaw & Co sold out of Nektar Therapeutics (NKTR) in Q2 2025, closing a stake of 7,679 shares — an estimated $78.3K sold.

D.E. Shaw & Co first reported a position in NKTR in Q2 2013 and held it in 47 quarters. The position peaked at $77.6M in Q1 2018. 109 funds tracked by Wall St. Rank hold NKTR as of Q2 2025.

  • D.E. Shaw & Co reported no remaining Nektar Therapeutics position as of Q2 2025 after selling out during the quarter.
  • D.E. Shaw & Co sold 7,679 Nektar Therapeutics shares in Q2 2025, an estimated $78.3K.
  • D.E. Shaw & Co first reported a position in Nektar Therapeutics in Q2 2013 and held it in 47 quarters.
  • D.E. Shaw & Co's Nektar Therapeutics position peaked at $77.6M in Q1 2018.
  • 109 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2025.

Based on D.E. Shaw & Co's 13F filing for Q2 2025, filed 14 Aug 2025.